Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with de novo acute myeloid leukemia and high-risk myelodysplastic syndrome aged over 70 years-Reference-Cited by-同舟云学术

Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with de novo acute myeloid leukemia and high-risk myelodysplastic syndrome aged over 70 years

Published:2021-01-01 Issue:1 Volume:26 Page:1040-1045
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Wang Fang¹,Xu Wenyan¹,Liu Li¹,Ren Xiuhong¹,Liu Pingping¹,Zheng Li¹,Zhang Hao¹,Zhang Songsong¹,Xu Yaru¹,Guo Zhenxing¹

Affiliation:

1. Department of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of China

Funder

Beijing Xisike Clinical Oncology Research Foundation

Beijing Huaxin Hospital Linghang Foundation

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2021.2009642

Reference32 articles.

1. United Nations. Department of economic and social affairs. Population DivisionWorld population prospects. The 2010 Revision. New York (NY): United Nations; 2011. (Report no. ST/ESA/SER.A/313)

2. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients

3. Management of Acute Myeloid Leukemia in Elderly Patients

4. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

5. Age and acute myeloid leukemia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted therapy;Medicines for Cancer;2023